All In Biotech

Drug Trial Radar · NCT03307980

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

A FACTOR IX (FIX) GENE TRANSFER, MULTI CENTER EVALUATION OF THE LONG TERM SAFETY AND EFFICACY STUDY OF PF 06838435 AND A DOSE ESCALATION SUBSTUDY IN INDIVIDUALS WITH HEMOPHILIA B

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

21

Actual

Start

Jun 22, 2017

Primary completion

Jul 23, 2026

Study completion Jul 23, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Long-term safety and efficacy follow-up for participants with Hemophilia B who were previously treated in the C0371005 (formerly SPK-9001-101) study, and a dose-escalation sub-study evaluating safety, tolerability, and kinetics of a higher dose with long-term safety and efficacy follow-up. Participants in the substudy do not need to have participated in C0371005.

Conditions

  • Hemophilia B

Interventions

  • PF-06838435 (formerly SPK-9001)Biological

    Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of PF-06838435 related adverse eventsTime frame: Baseline up to Year 6

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • UC Davis Ellison Ambulatory Care Clinic

    Sacramento, California

  • UC Davis Medical Center department of Radiology

    Sacramento, California

  • UC Davis Medical Center

    Sacramento, California

  • UC Davis Midtown Cancer Center

    Sacramento, California

  • UC DavisHealth Main Hospital

    Sacramento, California

  • LA Center for Bleeding and Clotting Disorders - Metairie

    Metairie, Louisiana

  • Tulane Lakeside Hospital

    Metairie, Louisiana

  • LA Center for Bleeding and Clotting Disorders

    New Orleans, Louisiana

  • Tulane University Clinical Translational Unit

    New Orleans, Louisiana

  • Tulane University Hospitals and Clinic

    New Orleans, Louisiana

  • Tulane University School of Medicine

    New Orleans, Louisiana

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • Louisiana Center for Advanced Medicine

    Slidell, Louisiana

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • Weill Cornell Medicine - New York Presbyterian Hospital

    New York, New York

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • McMaster University Medical Centre - Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • McMaster University

    Hamilton, Ontario, Canada

  • The Research Institute of the McGill University Health Centre

    Montreal, Quebec, Canada

  • McGill University Health Center - Research Institute

    Montreal, Quebec, Canada

  • Istanbul Universitesi Onkoloji Enstitusu Çocuk Hematoloji Onkoloji Bilim Dali

    Istanbul, Turkey (Türkiye)

  • Istanbul University Clinical Trials Excellence Center

    Istanbul, Turkey (Türkiye)

  • Ege Universitesi Tip Fakultesi Cocuk Sagligi ve Hastaliklari Anabilim Dali

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.